Business Context and Reporting Period
This Form 8-K filing by TherapeuticsMD, Inc. (TXMD) reports a corporate action effective as of May 3, 2022. The company, incorporated in Nevada, is a registrant on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital structure modification.
Material Changes
- Reverse Stock Split: The Company executed a 1-for-50 reverse stock split of its issued and outstanding common stock.
- Effective Date: The split became effective at 5:01 p.m. New York Time on May 6, 2022.
- Share Conversion: Every 50 shares of Common Stock were converted into 1 share.
- Authorized Shares: The number of authorized shares was reduced from 600,000,000 to 12,000,000.
- Fractional Shares: Fractional shares resulting from the split were rounded up to the nearest whole share.
- Trading Resumption: Trading on a split-adjusted basis under the symbol "TXMD" commenced on May 9, 2022.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or outlook. It notes that the reverse stock split did not require stockholder approval pursuant to Section 78.209 of the Nevada Revised Statutes.
Investor Verification Checklist
- Verify the adjusted share count and price per share on May 9, 2022, to confirm the 1-for-50 split execution.
- Confirm the reduction of authorized shares from 600 million to 12 million in subsequent filings.
- Review the treatment of fractional shares to ensure rounding up was applied correctly to individual holdings.
- Check for any subsequent filings regarding the company's compliance with Nasdaq listing standards following the split.